From collective restriction to critical action: the indirect effects of critical motivation and radical hope

IntroductionHistorically, Women of Color (WOC) in the United States have experienced systemic restrictions to their freedom and autonomy, which can have a lasting impact on their mental health and wellbeing. Conceptually, this type of collective autonomy restriction (CAR) experience may be associated with increased critical consciousness (CC), reflected in greater awareness of social and systemic oppression, commitment to and belief in one’s capacity to address social issues, and engagement in action; however, there is a dearth of research examining this association. Building on critical consciousness and hope literatures, we hypothesized that the association between CAR and critical action would be explained through serial pathways of increased critical motivation and greater radical or collective hope.Materials and MethodsA sample of 408 WOC completed an online survey administered through Prolific and hosted on Qualtrics. The survey included indicators of CAR, critical consciousness (critical motivation and critical actions), psychological hope, and radical hope. ResultsWe conducted structural equation modeling to test a serial mediation model exploring the associations among CAR, critical motivation, hope, and critical action. Findings indicated the association between CAR and critical action was fully mediated by the proposed serial mediation pathways (CAR → Critical Motivation → Radical Hope → Critical Action). The pathway through radical hope was stronger than through psychological hope. The direct effect of CAR on critical action was non-significant, indicating full mediation.DiscussionThese results highlight the role of radical hope as a potential pathway connecting critical awareness of collective autonomy restriction and critical motivation to engage in critical action aimed at social change. We extend the existing literature by demonstrating that awareness of oppression and motivation alone may be insufficient to explain the link between the first two dimensions of critical consciousness (critical reflection and critical motivation) and critical action. Limitations and implications for research and practice are discussed.

Ngā māuiui kai: a cross-sectional study of elevated eating disorder risk and related experiences among trans people in Aotearoa

PurposeLittle is known about disordered eating and eating disorders (ngā māuiui kai) among transgender and non-binary (trans) communities in Aotearoa New Zealand. This cross-sectional study sought to provide evidence of the prevalence and experiences of ngā māuiui kai among these communities.MethodsWe analyzed data from a national trans health survey of people using chi-square tests of independence to examine associations between sociodemographic characteristics and elevated eating disorder risk measured by the SCOFF screening tool. A content analysis of open-text survey comments identified themes across participants’ self-reported experiences of ngā māuiui kai.ResultsOverall, 34.3% of participants met criteria for increased risk for an eating disorder. Age, neurodivergence, material hardship, functional impairment, and Māori ethnicity were associated with elevated risk among this sample. No associations were found for gender, self-identified disability, or other ethnicities. The content analysis found that several participants reported connections between their māuiui kai and gender incongruence, broader mental health issues, or structural barriers. Some reported challenges seeking related healthcare, and a lack of providers’ awareness of the relationship between gender-affirming healthcare needs and ngā māuiui kai.ConclusionsA high proportion of trans participants met the criteria for elevated risk of eating disorders, with higher risk among those belonging to other marginalized groups. These findings highlight the unique risk factors among trans people who belong to multiple marginalized groups. They signal need for appropriate prevention and provision of responsive care for trans people at the intersections of ngā māuiui kai and gender-affirming healthcare.

How adolescent cannabis use reshapes the developing brain — a systematic review

Background and hypothesisCannabis use initiation during adolescence has increased globally, raising concerns about neurodevelopmental consequences during this critical period when the brain undergoes extensive remodeling in cannabinoid receptor-rich regions.Study designThis systematic review examines neurodevelopmental consequences of adolescent cannabis use, focusing on structural brain changes, cognitive impacts, addiction vulnerability, and long-term outcomes. We searched PubMed, EMBASE, PsycINFO, and Web of Science (2000-2025) for studies examining cannabis effects in adolescent populations. Following PRISMA guidelines, two reviewers screened 3,421 records and assessed 156 full-text articles, including studies with neuroimaging, cognitive assessments, or longitudinal follow-up.Study resultsThirty-six studies involving 8,432 participants met criteria: 23 longitudinal cohorts (62.2%), 8 cross-sectional (22.2%), 4 RCTs (11.1%), and 1 case-control study (2.8%). Neuroimaging revealed dose-dependent alterations including reduced prefrontal cortical and hippocampal/amygdala volumes, accelerated cortical thinning in longitudinal studies, and impaired white matter connectivity correlating with initiation age. Cognitive findings were mixed — some showed persistent deficits after prolonged abstinence in adolescent-onset users, others found no effects after controlling for confounders. Epidemiological studies consistently showed elevated addiction risk (ORs 3.9–7.2) in adolescents versus adults. Long-term associations included educational difficulties, mental health problems, and functional impairment, though causal relationships remained unclear.ConclusionsAdolescent cannabis use associates with structural brain changes, elevated addiction risk, and variable cognitive effects, suggesting greater vulnerability versus adult-onset use. However, methodological limitations including confounders, heterogeneous definitions, and observational designs limit causal inference. Findings support age-specific prevention and specialized interventions while highlighting needs for rigorous longitudinal research establishing causality.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifierCRD420251165329.

Case Report: Early onset pulmonary embolism following antipsychotic polypharmacy in an acute psychiatric setting

Pulmonary embolism (PE) is a potentially life-threatening condition that may occur in patients receiving antipsychotic medication. Several studies have shown an increased risk of venous thromboembolism (VTE) associated with the use of antipsychotics, particularly during the first weeks or months of treatment. However, very early onset of VTE within hours of treatment initiation has been rarely reported. We present the case of a 69-year-old woman who developed acute pulmonary embolism within a few hours after initiation of psychopharmacological treatment for a psychotic episode. Due to acute agitation, the patient received olanzapine, quetiapine, levomepromazine, and lorazepam. The patient had no known predisposing risk factors for VTE. Shortly after begin of psychopharmacological treatment she presented with deterioration of her general condition, soporous, hypotensive, tachycardic and with reduced oxygen saturation. PE was suspected clinically and confirmed by computed tomography pulmonary angiography. After diagnosis, PE was successfully treated with anticoagulation. This case is notable for the unusually rapid development of VTE, occurring within hours rather than the typically reported days to weeks. It underscores the need for heightened clinical vigilance even in the very early phase of antipsychotic therapy and in patients without risk factors for VTE.

Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism

Last December, news broke that the Centers for Disease Control and Prevention had awarded $1.6 million to a Danish vaccine research group to study the effects of the hepatitis B vaccine on infants in the West African nation of Guinea-Bissau. The proposed five-year study compared outcomes between infants vaccinated at birth and those vaccinated at six weeks of age. As a medical student and researcher, I was shocked by the brazen inequity of the trial. 

Randomized controlled trials have already demonstrated superior outcomes when the hepatitis B vaccine is administered at birth. More troubling, however, was the setting of the study. Guinea-Bissau is a highly endemic country for hepatitis B, where vaccination coverage lags behind global averages and roughly 60 percent of the population lives in poverty.

Read the rest…

What happened to Covid?

In April 2020, people around the globe were struggling to come to grips with the strictures of unprecedented societal shutdowns aimed at slowing the spread of Covid-19. Flattening the curve, in 2020-speak.

Six years later, school and business closures, mask wearing, and social distancing are dim, unpleasant memories. And Covid, though it still animates political animus plenty, feels like a threat from yesteryear. 

Read the rest…

STAT+: Doctor, wife of acting U.S. attorney general, appointed to NIH advisory council

Kristine Blanche, an integrative medicine doctor and wife of acting Attorney General Todd Blanche, has been named as a member to one of the advisory councils that provides critical funding recommendations to the National Institutes of Health. Her appointment, to serve on the advisory council to the National Center for Complementary and Integrative Health, is the first of such appointments to be made in over a year.

It’s unclear if Blanche’s selection — which has not been publicized by the NIH — is a sign of a thawing in the pipeline of advisory council appointments. But it’s done little to quiet simmering concerns among the wider research community about whether the Trump administration would attempt to stack councils with ideological allies who will use their positions to advance its political goals.  

It’s “the worst kind of political patronage,” Joshua Gordon, a former director of the National Institute of Mental Health, told STAT. He and others worry the move will erode taxpayers’ trust in how the largest funder of biomedical research in the world spends its $48 billion budget. “It’s clearly meant to contribute to an intentional degradation of confidence in the NIH.”

Continue to STAT+ to read the full story…

Lithuanian children’s trauma characteristics and correlates: comparison of clinical and non-clinical samples

IntroductionPrevious studies have shown that children’s exposure to potentially traumatic events and their trauma−related symptoms may not always be consistently identified. This study aims to examine differences in trauma exposure and related psychological outcomes between clinical and non−clinical Lithuanian children.MethodsThis cross-sectional study included 10–17−year−old children and adolescents recruited from a clinical inpatient setting (Vilnius University Hospital Santaros Klinikos) and general−education schools in Vilnius and nearby districts. After parental consent and child assent, participants completed a secure mobile assessment covering exposure to potentially traumatic events (CATS), dissociation (A−DES), mood and feeling (SMFQ), post−traumatic cognitions (CPTCI), PTSD symptoms (CATS; PCL−5 for convergent validation), and perceived social support (CASSS). Data were collected in 2023–2024. Group differences were examined using Welch’s t−tests (with Mann–Whitney U as robustness checks), and associations were assessed using Pearson correlations.ResultsIn the clinical sample over 40% of children experienced physical violence, while in the non−clinical sample 82.9% children reported exposure to multiple traumatic events. The clinical sample showed significantly higher dissociation, negative mood, and PTSD symptoms compared to the non−clinical sample. However, among children exposed to more than one traumatic event, differences in dissociation, PTSD symptoms, and close−friend support were not significant. Across both samples, exposure to potentially traumatic events was strongly associated with PTSD symptoms, dissociation, and post−traumatic cognitions, and moderately associated with mood symptoms. In the non−clinical sample, parental support showed moderate negative associations with dissociation, mood symptoms, post−traumatic cognitions, and PTSD symptoms.DiscussionThis study identified between−sample differences in exposure to potentially traumatic events and trauma−related psychological outcomes among Lithuanian children in inpatient and community settings, highlighting the need for trauma−informed assessment and attention to social support within child mental health and welfare services.

Medication Treatment for Tics and Tourette’s

There are several kinds of medication than can help kids with Tourette’s or another tic disorder. But it’s important to note that not all kids who develop tics need treatment. Tics are very common. They often go away on their own, and they tend to bother parents more than they do the children experiencing them. Drawing attention to them can make them worse. So doing nothing can be the best strategy — at least initially.

Treatment comes into play if tics are upsetting your child, giving them pain, or making it hard for them to function in everyday life — say they’re disrupting class or getting bullied because of their tics.

The first recommended step in treatment is a specialized form of therapy called comprehensive behavioral intervention for tics (CBIT). CBIT is centered on habit reversal training, in which the child learns to recognize when they have an urge to tic and substitute a competing response — an easier, more comfortable, or less noticeable action or behavior that makes the tic impossible. For instance, if a child’s tic is jerking their head to the side, the strategy might be to put their chin down instead.

But if therapy isn’t effective in reducing a child’s tics, medication can help.

Guanfacine and clonidine for tics

First-line medications for Tourette’s and other tic disorders are a class of drugs called alpha-2 agonists, explains Paul Mitrani, MD, PhD, a child and adolescent psychiatrist at the Child Mind Institute. Alpha agonists decrease the release of a neurotransmitter called norepinephrine, which stimulates the nervous system. Alpha agonists serve as a kind of dimmer switch — by calming down the system, they make the urge to tic less frequent, less intense, and by extension, easier to control.

The two alpha-2 agonists usually prescribed for tics are guanfacine and clonidine. Dr. Mitrani reports that he usually starts by prescribing guanfacine because it comes in a longer-acting form (Intuniv), which reduces symptoms for a full 24 hours. Clonidine’s long-acting form (Kapvay) is effective for 12 hours.

Dr. Mitrani adds that there is a new liquid form of clonidine called Onyda XR that lasts 24 hours, but there isn’t yet a strong body of evidence regarding its effectiveness for tics. Onyda XR is FDA-approved for ADHD, as are Kapvay and Intuniv.

While no alpha agonist medications are FDA-approved specifically for tics, Kapvay and Intuniv are frequently used off-label for them. There is ample research on their effectiveness for tics, and they are recommended by clinical practice guidelines.

Some children respond better to several doses of short-acting guanfacine or clonidine, Dr. Mitrani notes, rather than a smoother dose of a long-acting medication. This may be because medication can be timed to peak at times when kids need tic suppression most, such as at school.

Alpha agonists are the preferred first line medications for tic disorders because their side-effects, including drowsiness and low blood pressure, are relatively mild.

Antipsychotics for tics

If alpha agonists aren’t helping, the next step would be to try an antipsychotic medication, which can be more effective for treating tics, Dr. Mitrani notes, but their side effects are potentially more difficult to tolerate.

Aripiprazole (Abilify), which is FDA-approved for tics, is often Dr. Mitrani’s first choice among the antipsychotic medications. Abilify is a second-generation, or atypical, antipsychotic, a group of medications that have fewer side effects than older antipsychotics. Side effects of Abilify can include restlessness, agitation and weight gain.

Haloperidol (Haldol) is also effective for tics, but it’s an older antipsychotic with more side effect concerns, Dr. Mitrani notes. “I’ve only had one patient ever on Haldol, and he tolerated it well and it really helped with his tics when other things did not.”

Risperidone (Risperdal) is another atypical antipsychotic that can help, but its side effects tend to be worse than Abilify. Risperidone can cause more concerning weight gain and metabolic, neurological, and hormonal changes that can be harmful. Sometimes other medications are used to manage the weight gain from antipsychotics.

When kids with tics also have ADHD

More than three-quarters of kids diagnosed with a tic disorder also have another disorder. When a child has multiple disorders, a clinician will want to evaluate which is causing the child the most difficulty and prioritize treating that.

The most common co-occurring disorder with tics is ADHD. “If tics are the bigger problem, we would start with treating them,” says Dr. Mitrani. “If the ADHD is the bigger problem, which it typically is, we usually treat that first.”

In the past, it was recommended that children with tics and ADHD avoid stimulant medication, based on research that showed it made tics worse. But newer studies counter that finding, Dr. Mitrani notes, concluding that the old research was based on very high doses of amphetamine-based medications. To lower the risk of exacerbating tics, he recommends starting kids with ADHD and tics on methylphenidate-based medication.

“If your child is starting a stimulant,” he adds, “and you see worsening of tics — and it’s clearly related to when the stimulant is in their system — the best approach might be a lower dose of stimulant combined with guanfacine or clonidine.”

One advantage to that combination, he notes, is that kids with ADHD who have behavior problems can benefit from the guanfacine or clonidine being active in the mornings before the stimulant starts working and in the evenings when it’s out of their system.

Kids with other co-occurring disorders

When children with tics have other co-occurring disorders, such as anxiety, OCD, or depression, treating them with medication needs to be done very carefully, Dr. Mitrani says. Since children are typically not bothered by the tics themselves, it’s almost always the other disorder that is more problematic for them.  And, he adds, when the other problems cause distress, it can make the tics worse.

For anxiety, OCD, and depression, the first-line medication treatment is an antidepressant. Antidepressants can actually help alleviate tics indirectly, since they reduce anxiety. “Stress increases tics, so if there is significant anxiety and you treat the anxiety, the tics may get better,” Dr. Mitrani says. “And then maybe you don’t need the guanfacine or clonidine. But again, it depends on what the co-occurring disorders are and what’s the bigger problem for the child.”

Monitoring medication for tics

Due to the waxing and waning nature of tics, it can be challenging to see the full effect of medication and other interventions. It is important to give medication enough time to work, Dr. Mitrani notes, typically a few weeks, to see if the overall pattern, frequency, and severity of tics has improved. And children who are being treated should continue to be monitored regularly for any changes, as tics can recur or worsen, especially when a child is excited, tired, or experiencing more stress.

Most children with tics see a natural improvement or even resolution of tics as they progress through adolescence. If there seems to be a long-standing improvement, it is appropriate to consider reducing or stopping medication, especially if the child is experiencing side effects, Dr. Mitrani notes. If tics continue and are causing distress, it is important to keep treating them.

A child going off any of these medications — alpha agonists or antipsychotics — should do so gradually, by having their dose reduced over weeks or even longer, to avoid unpleasant or dangerous side effects of sudden withdrawal.

The post Medication Treatment for Tics and Tourette’s appeared first on Child Mind Institute.